Zoetis Inc.: A Global Leader in Animal Health

Zoetis Inc. is a leading global animal health company renowned for its expertise in the discovery, development, manufacture, and commercialization of veterinary vaccines and medicines. Headquartered in Parsippany, New Jersey, USA, Zoetis extends its operations across more than 100 countries, delivering a broad spectrum of products and services to veterinarians and livestock farmers worldwide.

Location and Facilities

Zoetis boasts a robust global presence, with key manufacturing, research, and commercial operations strategically located worldwide. The company's main research facilities are based in the United States, supplemented by significant international offices and production sites in countries including Belgium and Brazil. A notable facility includes the production site in Kalamazoo, Michigan, where Zoetis manufactures Dectomax-CA1, a critical product for livestock health.

Financial Indicators

In 2022, Zoetis reported impressive financial results, with a revenue of approximately $8.1 billion. The company consistently demonstrates strong financial health and a robust growth trajectory within the animal health sector. With a market capitalization around $80 billion, Zoetis commands significant market presence, reflecting strong investor confidence.

Important Company Events

A recent milestone for Zoetis is the conditional approval from the U.S. Department of Agriculture (USDA) for its avian influenza vaccine. Designed to protect poultry from the avian flu virus, this vaccine addresses a significant concern for poultry farmers and agricultural stability. This development highlights Zoetis' commitment to innovation in animal health and tackling emerging diseases.

Company Plans

Looking ahead, Zoetis aims to expand its product offerings and solidify its position in the veterinary vaccine market. The company is focused on sustainability and innovation, actively investing in research and development to discover innovative solutions that address global challenges in animal health. This includes expanding their vaccine portfolio to combat various diseases affecting livestock.

Zoetis is also advancing in genetic partnerships, exemplified by its collaboration with McCarty Family Farms and UNIFORM-Agri. Through these partnerships, Zoetis enhances decision-making for dairy producers using genetic insights and herd management software, underscoring its dedication to advancing the dairy industry. Additionally, Zoetis sponsors Dectomax CA-1, a drug authorized for use in various types of dairy cattle, including lactating and dry cows, as well as replacement heifers aged 20 months and older.

Modified: 2026/05/25

---